Patent · US Active

Oral suspension of prednisolone acetate

US8206727B2 · kind B2 · utility

6Cited by
15References
16Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 27, 2010
Grant dateJun 26, 2012
Priority date
Expiry dateAug 27, 2030

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P37/08
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to novel oral suspension formulation comprising prednisolone acetate, a pharmaceutically acceptable vehicle and a thickening agent. The present invention further provides a method of treating patients in need of prednisolone with the novel formulation.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.